Matthew Biegler
Stock Analyst at Oppenheimer
(2.80)
# 2,877
Out of 5,182 analysts
89
Total ratings
36.59%
Success rate
0.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Biegler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TYRA Tyra Biosciences | Maintains: Outperform | $36 → $50 | $36.92 | +35.43% | 7 | Feb 3, 2026 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Outperform | $750 → $865 | $744.44 | +16.19% | 1 | Feb 2, 2026 | |
| RLAY Relay Therapeutics | Upgrades: Outperform | $14 | $14.95 | -6.35% | 7 | Jan 26, 2026 | |
| OLMA Olema Pharmaceuticals | Maintains: Outperform | $45 → $48 | $15.29 | +213.93% | 10 | Dec 11, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Outperform | $45 | $23.37 | +92.55% | 1 | Dec 4, 2025 | |
| ORIC ORIC Pharmaceuticals | Maintains: Outperform | $12 → $15 | $10.19 | +47.20% | 6 | Nov 14, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Maintains: Outperform | $23 → $22 | $8.79 | +150.28% | 2 | Nov 13, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $30 → $28 | $16.49 | +69.80% | 3 | Oct 10, 2025 | |
| ACRV Acrivon Therapeutics | Maintains: Outperform | $9 → $8 | $1.88 | +325.53% | 4 | Aug 14, 2025 | |
| CTMX CytomX Therapeutics | Initiates: Outperform | $7 | $4.29 | +63.17% | 1 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $9 | $2.25 | +300.00% | 2 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $160 | $14.12 | +1,033.14% | 7 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $10.29 | +337.32% | 5 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $105 → $115 | $127.75 | -9.98% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $53 | $29.48 | +79.78% | 5 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $4.25 | +370.59% | 7 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $7.09 | - | 4 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $7.72 | +81.35% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $11.36 | - | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.31 | - | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.83 | - | 3 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.99 | - | 2 | Dec 22, 2022 |
Tyra Biosciences
Feb 3, 2026
Maintains: Outperform
Price Target: $36 → $50
Current: $36.92
Upside: +35.43%
Regeneron Pharmaceuticals
Feb 2, 2026
Reiterates: Outperform
Price Target: $750 → $865
Current: $744.44
Upside: +16.19%
Relay Therapeutics
Jan 26, 2026
Upgrades: Outperform
Price Target: $14
Current: $14.95
Upside: -6.35%
Olema Pharmaceuticals
Dec 11, 2025
Maintains: Outperform
Price Target: $45 → $48
Current: $15.29
Upside: +213.93%
Ascentage Pharma Group International
Dec 4, 2025
Initiates: Outperform
Price Target: $45
Current: $23.37
Upside: +92.55%
ORIC Pharmaceuticals
Nov 14, 2025
Maintains: Outperform
Price Target: $12 → $15
Current: $10.19
Upside: +47.20%
BridgeBio Oncology Therapeutics
Nov 13, 2025
Maintains: Outperform
Price Target: $23 → $22
Current: $8.79
Upside: +150.28%
Nurix Therapeutics
Oct 10, 2025
Maintains: Outperform
Price Target: $30 → $28
Current: $16.49
Upside: +69.80%
Acrivon Therapeutics
Aug 14, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $1.88
Upside: +325.53%
CytomX Therapeutics
Jul 31, 2025
Initiates: Outperform
Price Target: $7
Current: $4.29
Upside: +63.17%
May 14, 2025
Maintains: Outperform
Price Target: $10 → $9
Current: $2.25
Upside: +300.00%
Mar 21, 2025
Reiterates: Outperform
Price Target: $160
Current: $14.12
Upside: +1,033.14%
Feb 12, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $10.29
Upside: +337.32%
Dec 10, 2024
Reiterates: Outperform
Price Target: $105 → $115
Current: $127.75
Upside: -9.98%
Oct 29, 2024
Reiterates: Outperform
Price Target: $53
Current: $29.48
Upside: +79.78%
Sep 16, 2024
Reiterates: Outperform
Price Target: $20
Current: $4.25
Upside: +370.59%
Jul 2, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $7.09
Upside: -
May 14, 2024
Maintains: Outperform
Price Target: $16 → $14
Current: $7.72
Upside: +81.35%
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $11.36
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.31
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $2.83
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $0.99
Upside: -